It is suggested that the antiproliferative effect of metformin in therapeutic doses is due to indirect mechanisms, lowering of hyperglycemia, insulin and insulin resistance, IGF-1 and leptin levels, and it also decreases chronic inflammation and increases the blood levels of sex hormone binding globulin, which leads to reductions in circulating estrogen and androgens [33,35]. Here, LEP is linked to Insulin resistance.